EGFLAM and breast cancer: We further tested this model by disrupting GPR179-Pikachurin interaction by a dominant-negative strategy expressing the ectodomain of GPR179 in ON-BC to compete with endogenous GPR179 for Pikachurin binding (Figure 5E).